Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | FASN | P49327 | 14/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL12489351 | 0.88 | FASN (0.39) | MAPKAPK2FASN | |
| SCHEMBL13650611 | 0.81 | MAPKAPK2 (0.39) | MAPKAPK2FASNUSP2KDM4EALDH1A1 | |
| SCHEMBL13470632 | 0.80 | FASN (0.45) | FASNKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL26081076 | 0.77 | USP2 (0.37) | MAPKAPK2USP2CYP2D6TSHRSMN1; SMN2 | |
| SCHEMBL12489188 | 0.76 | FASN (0.51) | FASN | |
| SCHEMBL5474907 | 0.74 | MAPKAPK2 (0.51) | MAPKAPK2FASNUSP2ALDH1A1OPRD1 | |
| Hydrochloric Acid SCHEMBL12489013 | 0.73 | MAPKAPK2 (0.50) | MAPKAPK2FASNUSP2ALDH1A1OPRD1 | |
| SCHEMBL14782795 | 0.72 | LRRK2 (0.41) | USP2KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL14790128 | 0.71 | USP2 (0.35) | MAPKAPK2USP2KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL19416975 | 0.71 | HTT (0.35) | MAPKAPK2USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20220296605-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2022-09-22 | — | — | US | disclosed |
| US-11034690-B2 | Heterocyclic modulators of lipid synthesis | Saginiet Biosciences Inc. (US) | 2021-06-15 | — | — | US | disclosed |
| EP-3190108-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20190308969-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2019-10-10 | — | — | US | disclosed |
| US-20190269694-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2019-09-05 | — | — | US | disclosed |
| US-9809591-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| EP-3190108-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V Biosciences, Inc. (US) | 2017-07-12 | — | — | EP | disclosed |
| US-20170119786-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2017-05-04 | — | — | US | disclosed |
| US-20170119786-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2017-05-04 | — | — | US | disclosed |
| EP-2683244-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES INC (US) | 2017-02-01 | — | — | EP | disclosed |
| US-20160102091-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-20160102091-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-20140322355-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8871790-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871790-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20120264737-A1 | Heterocyclic Modulators of Lipid Synthesis | 3-V BIOSCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264737-A1 | Heterocyclic Modulators of Lipid Synthesis | 3-V BIOSCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| WO-2012122391-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264737-A1 | Heterocyclic Modulators of Lipid Synthesis | FASN, FADS1, FADS2 | MAPKAPK2 1403/4885FASN 1/4885USP2 2239/4885 |
| US-20140322355-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | MAPKAPK2 1403/4885FASN 1/4885USP2 2239/4885 |
| US-20170119786-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, SCD | MAPKAPK2 1189/4885FASN 1/4885USP2 2383/4885 |
| US-11034690-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, SCD | MAPKAPK2 1189/4885FASN 1/4885USP2 2383/4885 |
| US-20220296605-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, SCD | MAPKAPK2 1189/4885FASN 1/4885USP2 2383/4885 |
| US-20190308969-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, SCD | MAPKAPK2 1166/4885FASN 1/4885USP2 2220/4885 |
| US-20190269694-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, SCD | MAPKAPK2 1189/4885FASN 1/4885USP2 2383/4885 |
| US-20160102091-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | MAPKAPK2 1403/4885FASN 1/4885USP2 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.